Spironolactone therapy in older patients--the impact of renal dysfunction

Area of Science:

• Cardiology
• Pharmacology
• Nephrology

Background:

• Low-dose spironolactone is recognized for reducing mortality in heart failure.
• Elderly patients with congestive heart failure (CHF) are a vulnerable population.
• Potassium homeostasis is critical, particularly in patients with renal impairment.

Purpose of the Study:

• To investigate the effects of spironolactone on potassium levels in elderly CHF patients.
• To identify risk factors for hyperkalemia in this cohort.
• To evaluate dose adjustment strategies for managing hyperkalemia.

Main Methods:

• A cohort of 18 elderly patients (>70 years) with CHF (NYHA Grade II-IV) were enrolled.
• Patients started on 25 mg daily spironolactone, with dose reduction to 12.5 mg if hyperkalemia (K+ >5.0 mmol/l) occurred.
• Serum creatinine, urea, electrolytes (Na+, K+), blood pressure, and pulse were monitored at baseline and regularly throughout the study.

Main Results:

• Nine patients had renal impairment (RI; serum creatinine >150 micromol/l), exhibiting higher baseline serum potassium (4.56 vs. 4.04 mmol/l).
• Six patients with RI developed hyperkalemia compared to one without RI (P<0.05).
• Reducing spironolactone to 12.5 mg daily normalized serum potassium in all patients, except one requiring withdrawal.

Conclusions:

• Elderly CHF patients with renal impairment are at higher risk of developing hyperkalemia with spironolactone.
• A reduced daily dose of 12.5 mg spironolactone effectively normalizes serum potassium.
• Frequent serum potassium monitoring is crucial for older CHF patients initiating spironolactone, especially those with renal impairment.